Preoperative evaluation of mammographic microcalcifications after neoadjuvant chemotherapy for breast cancer

• Published in: Clinical radiology Vol. 75; no. 8; pp. 641.e19 - 641.e27
• Main Authors: Kim, E.Y., Do, S.-I., Yun, J.-S., Park, Y.L., Park, C.H., Moon, J.H., Youn, I., Choi, Y.J., Ham, S.-Y., Kook, S.H.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.08.2020
• Subjects: Antineoplastic Agents - therapeutic use; Breast - diagnostic imaging; Breast Neoplasms - diagnosis; Breast Neoplasms - drug therapy; Breast Neoplasms - surgery; Calcinosis - diagnosis; Female; Humans; Mammography - methods; Middle Aged; Neoadjuvant Therapy; Preoperative Care - methods
• ISSN: 0009-9260; 1365-229X
• DOI: 10.1016/j.crad.2020.03.024

To assess the predictive value of preoperative residual mammographic microcalcifications for residual tumours after neoadjuvant chemotherapy (NAC) for breast cancer. This single-centre retrospective study included breast cancer patients who underwent NAC and demonstrated suspicious microcalcifications within or near the tumour bed on mammography from June 2015 to August 2018. The residual microcalcifications and remnant lesion on magnetic resonance imaging (MRI) were correlated with histopathological findings of residual tumours and immunohistochemical markers. A total of 96 patients were included. Ten patients achieved pathological complete response (pCR) and previous suspicious microcalcifications were associated with benign pathology in 10.4% (10/96) of the patients. In the remaining 86 patients who did not achieve pCR, 61.5% (59/96) of the residual microcalcifications were associated with invasive or in situ carcinoma and 28.1% (27/96) with benign pathology. Hormone receptor-positive (HR+) patients had the highest proportion of residual malignant microcalcifications compared to HR− patients (48.9% versus 13.5%, respectively; p=0.019). MRI correlated better than residual microcalcifications on mammography in predicting residual tumour extent in all subtypes (ICC=0.709 versus 0.365). MRI also showed higher correlation with residual tumour size for the HR−/HER2+ and HR−/HER2- subtype (ICC=0.925 and 0.876, respectively). The extent of microcalcifications on mammography after NAC did not correlate with the extent of residual cancer in 38.5% of women. Regardless of the extent of microcalcifications, residual tumour extent on MRI after NAC and molecular subtype could be an accurate tool in evaluating residual cancer after NAC. •Residual microcalcifications after neoadjuvant chemotherapy in breast cancer.•Extent of microcalcifications after NAC did not correlate with residual cancer.•Residual tumor extent on MRI accurate tool in evaluating residual cancer after NAC.